EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers

VYu Skryabin, A E Petukhov, S A Pozdniakov, V A Ivanchenko, I A Zaytsev, S S Miroshkin, S I Sokolova, I V Bure, V V Smirnov, D A Sychev

Psychopharmacology Bulletin · 2025

DOI: 10.64719/pb.4511 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychopharmacology Bulletin, 2025. Verfasst von VYu Skryabin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Ru…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Hallucinations, Precision Medicine, Haloperidol. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alcoholic hallucinosis (AH) is one of the severe complications of chronic alcoholism, characterized by psychotic symptoms such as auditory hallucinations and delusions. Haloperidol is widely used to treat AH; however, its therapy is often complicated by side effects. A personalized approach using pharmacogenetic testing (particularly the CYP2D6 polymorphism) allows individualization of haloperidol dosage, improving both safety and efficacy of therapy. Materials and Methods The study included 100 men diagnosed with “psychotic disorder induced by alcohol use.” Patients were randomized into two groups: the main group (45 patients) received haloperidol based on the results of pharmacogenetic testing, while the control group (55 patients) received standard dosing. Genotyping was conducted for the CYP2D6 1846G > A polymorphism. The effectiveness was assessed using the PANSS, UKU, and SAS scales.

Results

Genotyping showed an even distribution of CYP2D6 polymorphisms in both groups. The main group demonstrated a significant reduction in side effects and improvement in psychotic symptoms compared to the control group. Differences on the UKU, SAS, and PANSS scales reached statistical significance on days 3–5 of treatment.

Conclusion

Using pharmacogenetic testing to adjust haloperidol dosage improves therapy tolerability and accelerates the resolution of psychotic symptoms in patients with alcoholic hallucinosis, confirming the feasibility of a personalized approach in psychopharmacotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6HallucinationsPrecision MedicineHaloperidolAlcoholismAntipsychotic AgentsHumansMaleAdultMiddle AgedPharmacogenomic TestingDose-Response Relationship, DrugGenotypePharmacogenetics

Stichwörter der Autor:innen

CYP2D6alcoholic hallucinosishaloperidolpersonalized medicinepharmacogeneticspsychopharmacotherapy

Substanzen

Cytochrome P-450 CYP2D6HaloperidolAntipsychotic Agents

Autor:innen und Institutionen

  • Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia; Associate professor of addiction psychiatry department, Russian…
  • Petukhov, PhD, MD, clinical laboratory diagnostician of the analytical toxicology lab of the Reference center for psychoactive substances use monitoring, Moscow Research and Practical Centre on Addictions of the Moscow…
  • Pozdniakov, researcher of the laboratory of genetics and fundamental studies, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Ivanchenko, laboratory assistant, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Zaytsev, laboratory assistant, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Miroshkin, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.

Zitieren

APA

Skryabin, V., Petukhov, A. E., Pozdniakov, S. A., Ivanchenko, V. A., Zaytsev, I. A., Miroshkin, S. S., Sokolova, S. I., Bure, I. V., Smirnov, V. V., & Sychev, D. A. (2025). Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4511

Vancouver

Skryabin V, Petukhov AE, Pozdniakov SA, Ivanchenko VA, Zaytsev IA, Miroshkin SS, et al. Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers. Psychopharmacology Bulletin. 2025. doi:10.64719/pb.4511

BibTeX
@article{Skryabin2025,
  author = {Skryabin, VYu and Petukhov, A E and Pozdniakov, S A and Ivanchenko, V A and Zaytsev, I A and Miroshkin, S S and Sokolova, S I and Bure, I V and Smirnov, V V and Sychev, D A},
  title = {Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers},
  journal = {Psychopharmacology Bulletin},
  year = {2025},
  doi = {10.64719/pb.4511}
}
Kostenlos starten →